Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium

被引：0
|
作者：
Van, Nooten F. [1 ]
Dewilde, S. [1 ]
Van Belle, S. [2 ]
Marbaix, S. [3 ]
机构：
[1] United BioSource Corp, Brussels, Belgium
[2] State Univ Ghent Hosp, B-9000 Ghent, Belgium
[3] Pfizer, Brussels, Belgium
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A329 / A329
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of new targeted therapy sunitinib malate as second line treatment in metastatic renal cell carcinoma in Argentina
    Aiello, E. C.
    Muszbek, N.
    Richardet, E.
    Lingua, A.
    Charbonneau, C.
    Remak, E.
    VALUE IN HEALTH, 2007, 10 (03) : A127 - A128
  • [2] Cost-effectiveness of sunitinib in metastatic renal cell carcinoma
    Purmonen, Timo T.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (04) : 383 - 393
  • [3] Cost-effectiveness of taxanes as second line agents in treatment of metastatic breast cancer
    Kawatkar, AA
    Hay, JW
    VALUE IN HEALTH, 2006, 9 (03) : A108 - A108
  • [4] A COST-EFFECTIVENESS ANALYSES OF USING SUNITINIB (SU) IN FIRST LINE OF METASTATIC RENAL CANCER IN ROMANIAN JURISDICTION
    Berghea, F.
    Skoupa, J.
    Ciuleanu, T.
    Miron, L.
    Stanculeanu, D. L.
    Jinga, D.
    Dediu, M.
    Mateescu, D. N.
    Hajek, P.
    Bradatan, B.
    Xuan, J.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A412
  • [5] COST-EFFECTIVENESS OF PAZOPANIB COMPARED TO SUNITINIB IN THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA
    Fouad, A.
    Atia, A.
    Omar, Y.
    Shawky, M.
    Sakr, M.
    VALUE IN HEALTH, 2016, 19 (07) : A733 - A734
  • [6] Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
    Mihajlovic, Jovan
    Pechlivanoglou, Petros
    Sabo, Ana
    Tomic, Zdenko
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1909 - 1922
  • [7] COST EFFECTIVENESS OF EVEROLIMUS FOR SECOND LINE TREATMENT OF METASTATIC RENAL CELL CANCER IN SERBIA
    Mihajlovic, J.
    Pechlivanoglou, P.
    Sabo, A.
    Tomic, Z.
    Postma, M. J.
    VALUE IN HEALTH, 2012, 15 (07) : A427 - A427
  • [8] Does first-line treatment impact the cost-effectiveness of second-line treatment for elderly metastatic colon cancer patients?
    Mullins, C. Daniel
    Woldemichael, Andinet
    Zheng, Zhiyuan
    Onukwugha, Ebere
    Seal, Brian S.
    Hanna, Nader
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [9] COST-EFFECTIVENESS ANALYSIS OF FULVESTRANT IN THE TREATMENT OF METASTATIC BREAST CANCER IN SECOND-LINE CHEMOTHERAPY
    Krysanov, I
    Krysanova, V
    VALUE IN HEALTH, 2014, 17 (07) : A637 - A637
  • [10] Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
    Lin, Jingyang
    Fang, Qingxia
    Zheng, Xiaochun
    PLOS ONE, 2023, 18 (02):
12345